synovial sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The gold standard for SS diagnosis is characterization of the t(X;18) chromosomal translocation.
|
29490565 |
2018 |
synovial sarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Synovial sarcomas are deadly soft tissue malignancies associated with t(X;18) balanced chromosomal translocations.
|
28851813 |
2017 |
synovial sarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Oncogenesis in synovial sarcoma is driven by the chromosomal translocation t(X,18; p11,q11), which generates an in-frame fusion of the SWI/SNF subunit SS18 to the C-terminal repression domains of SSX1 or SSX2.
|
25614489 |
2015 |
synovial sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results emphasize t(X;18) as a single initiating event in SS and as the main oncogenic driver.
|
26415226 |
2015 |
synovial sarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ultimately, an immunohistochemical stain for TLE-1 demonstrated diffusely strong nuclear positivity and molecular studies showed the presence of the t(X; 18) SYT/SSX1 translocation confirming the diagnosis of SS.
|
24436244 |
2014 |
synovial sarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Unusual primary intracranial dural-based poorly differentiated synovial sarcoma with t(X; 18)(p11; q11).
|
22537253 |
2013 |
synovial sarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Synovial sarcoma (SS) is a malignant soft tissue tumor harboring chromosomal translocation t(X; 18)(p11.2; q11.2), which produces SS-specific fusion gene, SYT-SSX.
|
23313505 |
2013 |
synovial sarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Whereas the importance of the t(X;18) translocation in SS oncogenesis is well established, the genetic basis of SS metastasis is still poorly understood.
|
23319690 |
2013 |
synovial sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our objectives in this study were (1) to test whether the differentially expressed gene, Transducin-Like Enhancer of split (TLE1) belonging to the groucho/TLE family, is also distinct on the protein level; (2) to evaluate this biomarker in a series of well-characterised synovial sarcomas on standard, full-sized tissue sections and (3) to correlate the expression of TLE1 with t(X;18) and other established biomarkers.
|
20189377 |
2010 |
synovial sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Synovial sarcoma (SS) is characterized by the t(X; 18) (p11.2; q11.2) translocation resulting in the SYT-SSX fusion transcript, detectable by reverse transcriptase polymerase chain reaction (RT-PCR).
|
19267417 |
2009 |
synovial sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytogenetic analysis was performed of six monophasic synovial sarcomas (four primary, two recurrent tumors) and one recurrent poorly differentiated synovial sarcoma with complex tumor-specific t(X;18).
|
19215793 |
2009 |
synovial sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Karyotype on fresh tissue represents a genome-wide screen of gross chromosomal alterations, whereas fluorescence in situ hybridization and polymerase chain reaction detect specific defects that are characteristic of a given tumor type such as t(11;22) EWSR1-FLI1 in Ewing family tumors, t(X;18) SS18-SSX1 in synovial sarcoma, t(2;13) PAX3-FOXO1A in alveolar rhabdomyosarcoma, and MYCN gene amplification in neuroblastoma.
|
19214114 |
2009 |
synovial sarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Synovial sarcoma is a tumor of the soft tissues with a unique chromosomal translocation t(X;18)(p 11.2;q11.2) that can be detected by polymerase chain reaction in tissue homogenates.
|
18325475 |
2008 |
synovial sarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The SYT-SSX fusion protein down-regulates the cell proliferation regulator COM1 in t(x;18) synovial sarcoma.
|
17101797 |
2007 |
synovial sarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent findings on the molecular background of synovial sarcoma with the description of the specific translocation t(X;18) led to the incorporation of this particular genetic aberration into the definition of this tumor type.
|
17509396 |
2007 |
synovial sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To determine whether the t(X;18) present in the original tumor is maintained in its passages, a dual-color break-apart FISH assay for SYT gene disruption was performed in two tissue microarrays (TMA) comprising eight molecularly confirmed primary SSs and their xenografts, which were followed for several generations.
|
17175375 |
2007 |
synovial sarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytogenetic analysis confirmed the t(X;18) in all six synovial sarcomas and the t(11;22) in three Ewing sarcomas.
|
16557276 |
2006 |
synovial sarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We report here the molecular cytogenetic analyses of a synovial sarcoma of the larynx harboring the diagnostic t(X;18), as well as trisomies 2 and 8.
|
15325093 |
2004 |
synovial sarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Characteristic sequence motifs located at the genomic breakpoints of the translocation t(X;18) in synovial sarcomas.
|
12687023 |
2003 |
synovial sarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The t(X;18) translocation is a specific marker of synovial sarcomas (SS).
|
14669292 |
2003 |
synovial sarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Detection of the t(X:18) translocation using RT-PCR, Southern blot, and DNA sequencing definitively confirmed the diagnosis of SS.
|
12552937 |
2003 |
synovial sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The t(X;18) (p11.2;q11.2) has been demonstrated to be highly characteristic of synovial sarcomas, and the resulting SYT-SSX fusion transcripts have been shown to be useful diagnostic markers.
|
11826189 |
2002 |
synovial sarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This case illustrates the importance of proper procurement of frozen tissue for molecular genetic analysis for the identification of the t(X;18), characteristic of synovial sarcoma.
|
11845884 |
2002 |
synovial sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, in keeping with literature data, our results show that reactivity for epithelial membrane antigen, cytokeratin AE1/AE3, and E-cadherin, in combination with CD34 negativity, are the most useful and sensitive markers for diagnosing monophasic fibrous and poorly differentiated t(X;18)-positive SS.
|
12409719 |
2002 |
synovial sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Submandibular synovial sarcoma with t(X;18) and synovial sarcoma of the toe with additional cytogenetic abnormalities: presentation of two cases and review of the literature.
|
12034530 |
2002 |